



PRESS RELEASE

EMULTECH AND TO-BBB ANNOUNCE DEVELOPMENT PARTNERSHIP

The drug delivery development company EmulTech and the brain drug delivery company to-BBB have announced a collaborative partnership.

EmulTech is a contract development organization for drug delivery systems using its superior micro particle technology, called Emulsion Technology for Micro Encapsulates (ET4ME). The highly versatile process provides solutions to many current market demands, including uniformity, reproducibility issues. Starting with small-scale feasibility studies, EmulTech is able to quickly test various formulations, requiring only small volumes. Its parallel scale up strategy allows for swift and reproducible scale up.

to-BBB is a private biotechnology company focusing on enhanced drug delivery across the blood-brain barrier. Based on its proprietary G-Technology®, to-BBB is developing brain-targeted liposomes. These liposomes are coated with the endogenous antioxidant glutathione at the tips of polyethylene glycol (PEG) to safely enhance the delivery to the brain.

Fränk de Jong, CEO, EmulTech says: “We are excited about this collaboration. It fits our development philosophy in which we aim to set up long-term collaborations with our partners and customers for the development of various application platforms. The liposomal platform for CNS related treatments together with to-BBB is one of the applications that show the versatility of our technology.”

“We are very pleased to collaborate with Emultech,” says Pieter Gaillard, CSO of to-BBB. “to-BBB’s brain delivery technology combined with Emultech’s microencapsulation expertise, should result in substantial progress towards the development of innovative medicines for untreated CNS diseases.”

About Emultech

EmulTech is a contract development organization focused on providing solutions in the field of advanced drug delivery systems. In close collaboration with customers and partners EmulTech quickly and cost efficiently develops the requested drug delivery system to specification. In the process EmulTech also ensure that its systems are scaled up and tailored to provide the required volumes of cGMP material in a robust manner. At the moment EmulTech is involved in various collaborations in Europe and the United States with different companies and hospitals ranging from top ten pharmaceutical companies to small biotech organizations.

About to-BBB

to-BBB is a clinical stage biotechnology company focusing on enhanced drug delivery across the blood-brain barrier. The Company is developing novel treatments for devastating brain disorders, such as brain

cancer, neurodegenerative diseases and lysosomal storage diseases, by combining existing drugs with the G-Technology[®], to-BBB's proprietary brain delivery platform. This technology combines the widely used drug delivery approach of pegylated liposomes with the endogenous tripeptide glutathione as targeting ligand in a novel and safe way. Together with several top tier pharma and biotech companies, to-BBB is investigating the versatility of the G-Technology[®] for drugs that are unable to reach the brain within a tolerable therapeutic window. to-BBB is applying the G-Technology[®] for the delivery of doxorubicin for the treatment of brain cancer as its internal lead product 2B3-101.

to-BBB is headquartered in The Netherlands at the Leiden Bio Science Park and established a fully owned subsidiary, to-BBB Taiwan Ltd., in Taipei, Taiwan. Investors in to-BBB include Aescap Venture, Antea Participaties, Jonghoud International and the Industrial Bank of Taiwan Management Corporation (IBTM).

to-BBB Contacts

Willem van Weperen, MSc, MBA
Chief Executive Officer
to-BBB technologies BV
Tel: +31 71 3322252
vanweperen@toBBB.com

Pieter Gaillard, PhD
Chief Scientific Officer
to-BBB technologies BV
Tel: +31 71 3322251
gaillard@toBBB.com

Emultech Contacts

Fränk de Jong M.Sc.
Chief Executive Officer
EmulTech BV
Tel: +31 40 247 5548
DeJong@EmulTech.nl

Robin de Bruijn
Chief Technology Officer
EmulTech BV
Tel: +31 40 247 4922
DeBruijn@EmulTech.nl

For more information about EmulTech, please visit www.EmulTech.nl and for more information about to-BBB please visit www.tobbb.com.